In this issue:
CheckMate 649: Front-line nivolumab/chemotherapy optimal for gastric cancer
Artificial sweeteners linked to cancer risk
Adjuvant chemotherapy extends survival in gastric cancer patients with a LNR ≥ 9%
Perioperative CAPOX for stage 3 gastric cancer
Inactivity increases risk of mortality in cancer survivors
Marked increase in the global cancer burden
Concurrent radiotherapy with immunotherapy does not increase adverse events
Post hoc analysis finds no risk of immunotherapy-mediated hyper-progression
Neoadjuvant immunotherapy plus chemotherapy promising for oesophageal SCC
Imatinib plus binimetinib for front-line treatment of advanced GIST
Please login below to download this issue (PDF)